AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baum, S. E.
Right arrow Articles by Jorgensen, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baum, S. E.
Right arrow Articles by Jorgensen, J. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2002, p. 3094-3095, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3094-3095.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Comparative Activities of the Oxazolidinone AZD2563 and Linezolid against Selected Recent North American Isolates of Streptococcus pneumoniae

Sue E. Baum,1 Sharon A. Crawford,2 M. L. McElmeel,2 Cynthia G. Whitney,3 and James H. Jorgensen2*

Infectious Disease Service of Brooke Army Medical Center,1 University of Texas Health Science Center, San Antonio, Texas,2 Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia3

Received 8 February 2002/ Returned for modification 2 May 2002/ Accepted 5 June 2002


   ABSTRACT
Top
 Abstract
Text
 References
 
The activity of AZD2563 against 250 highly resistant pneumococci and 267 drug-susceptible isolates was determined. The AZD2563 MICs for 50 and 90% of the strains tested were 1 and 2 µg/ml and 0.5 and 1 µg/ml, respectively, for the two isolate groups. These MICs were within 1 log2 dilution of those of linezolid.


   TEXT
Top
 Abstract
 Text
References
 
The incidence of penicillin resistance and multidrug resistance in Streptococcus pneumoniae has continued to increase (3, 8, 13) and has altered empirical choices of therapy for invasive pneumococcal infections (1, 2, 5, 6). Multidrug resistance to three or more drug classes (13) has made therapy for serious infections challenging, especially in severely ill patients. Resistance to traditional choices for therapy of pneumococcal infections (e.g., ß-lactams, macrolides) has prompted investigation of the activities of newer agents (e.g., fluoroquinolones, ketolides, carbapenems, and oxazolidinones) for predictable activity against highly resistant strains.

Linezolid was approved by the U.S. Food and Drug Administration in 2000 and represents the first oxazolidinone compound to reach clinical use. It is indicated for therapy of serious infections due to resistant staphylococci or enterococci and also for community-acquired pneumonia due to S. pneumoniae. Oxazolidinones bind to the 50S ribosomal subunit and inhibit protein synthesis by a unique mechanism that does not appear to share cross-resistance with other protein synthesis inhibitors (4). Although resistance to linezolid has been found in Enterococcus isolates (G. E. Zurenko, W. M. Todd, B. Hafkin, B. Meyers, C. Kauffman, J. Bock, J. Slighton, and D. Shinabarger, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 848, 1999) and more recently in Staphylococcus aureus (12), it has not been found in S. pneumoniae or other streptococci. AZD2563 is a newer member of the oxazolidinone class that is currently under development.

Two hundred fifty isolates of S. pneumoniae with previously determined resistance to one or more of the antimicrobial agents currently in use were tested against AZD2563 and selected comparative agents. A group of 267 drug-susceptible, invasive pneumococcal isolates were chosen from among the 1998 to 2000 Centers for Disease Control and Prevention Active Bacterial Core Surveillance/Emerging Infections Program collection. MICs of AZD2563, linezolid, quinupristin-dalfopristin, erythromycin, clindamycin, penicillin, levofloxacin, and vancomycin were determined by the broth microdilution method recommended by the NCCLS (10). This included cation-adjusted Mueller-Hinton broth supplemented with 3% lysed horse blood prepared as frozen microdilution panels (Trek Diagnostic Systems Inc., Westlake, Ohio), an inoculum of approximately 5 x 105 CFU/ml, and incubation at 35°C for 20 to 24 h in ambient air prior to visual MIC determination. S. pneumoniae ATCC 49619 was included with each day's testing as a control organism.

Susceptibility results obtained for the entire collection of 517 S. pneumoniae isolates with AZD2563 and the other comparator agents are depicted in Table 1. Among the drug-susceptible isolates, the MICs of AZD2563 for 50 and 90% of the isolates tested (MIC50 and MIC90, respectively) were 0.5 and 1.0 µg/ml, respectively, versus 1 and 2 µg of linezolid per ml. Among the drug-resistant isolates, the MIC50 and MIC90 were 1 dilution higher and identical to those of linezolid for this group. For both groups of isolates, the MIC90 for AZD2563 was 2 µg/ml.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Susceptibilities of selected S. pneumoniae clinical isolates to AZD2563, linezolid, and representative agents of various other antimicrobial classes

 
Figure 1 shows the distributions of linezolid and AZD2563 MICs for the drug-resistant and drug-susceptible groups, respectively. The geometric mean MICs of AZD2563 were 0.70 and 0.94 µg/ml for the susceptible and resistant groups, respectively, compared to 0.99 and 1.14 µg/ml, respectively, for linezolid. For 218 isolates, the MICs of linezolid and AZD2563 were different. For 211 (96.8%) of these, the AZD2563 MIC was lower than that of linezolid. Of these, one was lower by 2 dilutions; all others were lower by a single dilution. In seven cases (3.2%), the MIC was lower by a single dilution for linezolid. MICs of linezolid were never lower than those of AZD2563 by more than a single dilution.



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 1. MICs (micrograms per milliliter) of AZD2563 (AZD) and linezolid (LZD) for 250 drug-resistant S. pneumoniae isolates (A) and 267 drug-susceptible S. pneumoniae isolates (B).

 
Because of the rising rate of resistance in pneumococci and the potential for development of resistance to antibiotics that have thus far been universally active, new agents are needed to provide predictable activity against multidrug-resistant strains. Linezolid has been shown to have almost universal activity against multiply resistant isolates of enterococci, staphylococci, and S. pneumoniae (7). The newer oxazolidinone AZD2563 has been shown in this study to have activity very similar to that of linezolid against highly resistant, as well as susceptible, recent clinical isolates of S. pneumoniae from geographically diverse regions of the United States. While susceptibility breakpoints have not been determined for AZD2563, the MIC50 and MIC90 of AZD2563 appear to be similar to or slightly lower than those of linezolid. Pharmacokinetic data regarding levels of AZD2563 in blood, cerebrospinal fluid, and other bodily fluid are needed to put into perspective this slightly greater potency of AZD2563. The isolates included in this study were representative of all known resistance phenotypes of S. pneumoniae (including ß-lactam, macrolide, lincosamide, fluoroquinolone, and streptogramin resistance), and regardless of the phenotype selected, all isolates were inhibited by AZD2563 at <=2 µg/ml. Thus, as with linezolid, no cross-resistance to AZD2563 and other classes of antibiotics was observed. This may be a result of the unique mechanism of action of the oxazolidinones, which appears to be inhibition of translation of rRNA (9).

Linezolid has been demonstrated to be effective in the treatment of several serious gram-positive infections, including community-acquired pneumonia (11). Given the similar activities of AZD2563 and linezolid against S. pneumoniae, AZD2563 could also prove to be useful for therapy in patients with severe infections caused by resistant organisms. Additional studies are needed to determine its pharmacokinetics, safety, and in vivo clinical efficacy against invasive pneumococcal infections in humans.


   ACKNOWLEDGMENTS
 
This investigation was supported in part by a grant from Astra Zeneca Pharmaceuticals.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900. Phone: (210) 567-4088. Fax: (210) 567-2367. E-mail: jorgensen{at}uthscsa.edu. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Appelbaum, P. C. 2000. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 31(Suppl.):S29-S34.
  2. Bartlett, J. G., S. F. Dowell, L. A. Mandell, T. M. File, D. M. Musher, and M. J. Fine. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31:347-382.[CrossRef][Medline]
  3. Doern, G. V., A. B. Brueggemann, H. Huynh, E. Wingert, and P. Rhomberg. 1999. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998. Emerg. Infect. Dis. 5:757-765.[Medline]
  4. Fines, M., and R. Leclercq. 2000. Activity of linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J. Antimicrob. Chemother. 45:797-802.[Abstract/Free Full Text]
  5. Friedland, I. R., and G. H. McCracken. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.[Free Full Text]
  6. Heffelfinger, J. D., S. F. Dowell, J. H. Jorgensen, K. P. Klugman, L. R. Mabry, D. M. Musher, J. F. Plouffe, A. Rakowsky, A. Schuchat, C. G. Whitney, and The Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. 2000. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch. Intern. Med. 160:1399-1408.[Abstract/Free Full Text]
  7. Johnson, A. P., M. Warner, and D. M. Livermore. 2000. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J. Antimicrob. Chemother. 45:225-230.[Abstract/Free Full Text]
  8. Jones, R. N., S. G. Jenkins, D. J. Hoban, M. N. Pfaller, and R. Ramphal. 2000. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY antimicrobial surveillance program, 1997-1998. Diagn. Microbiol. Infect. Dis. 37:93-98.[Medline]
  9. Matassova, N. B., M. V. Rodnina, R. Endermann, H. P. Kroll, U. Pleiss, H. Wild, and W. Wintermeyer. 1999. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 5:939-946.[Abstract]
  10. NCCLS. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. NCCLS, Wayne, Pa.
  11. Plouffe, J. F. 2000. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid. Clin. Infect. Dis. 31(Suppl. 4):S144-S149.
  12. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennerstein, L. Venkataraman, R. C. Moellering, and M. J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.[CrossRef][Medline]
  13. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. R. Cieslak, M. Cetron, E. R. Zell, J. H. Jorgensen, and A. Schuchat. 2000. Increasing prevalence of multidrug resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, September 2002, p. 3094-3095, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.3094-3095.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baum, S. E.
Right arrow Articles by Jorgensen, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baum, S. E.
Right arrow Articles by Jorgensen, J. H.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS